Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

ALLHAT education campaign

Executive Summary

The National Heart, Lung and Blood Institute announces a three year, $3.7 mil. initiative to educate physicians and patients about hypertension findings from the ALLHAT trial. The study's main finding was that generic diuretic chlorthalidone is superior to Pfizer's calcium channel blocker Norvasc (amlodipine) and ACE inhibitors in preventing cardiovascular outcomes. The campaign, funded by NHLBI, will be implemented in collaboration with the National High Blood Pressure Education Program. Approximately 150 physicians in 34 states have completed training to lead educational sessions with physician peers. Educators will conduct one session per month and are expected to reach nearly 30,000 physicians by September 2006. Cardiologists have expressed concern about the translation of ALLHAT findings into clinical practice. (1"The Pink Sheet" June 27, 2005, p. 20)...

You may also be interested in...



Antihypertensive Cardio Labeling Should Be Applied To New Classes – Cmte.

Class labeling for reduction of cardiovascular outcomes based on blood pressure lowering should be applied to new classes of antihypertensives, members of FDA's Cardiovascular & Renal Drugs Advisory Committee said

EU MDR Notified Body Designations Could Soar By A Third By End Of 2021

There could be 28 notified body designations in total under the Medical Device Regulation by the end of 2021. But there is cause for concern over designations under the IVD Regulation, which are lagging far behind.

Swiss Health Providers Turn Heat On Federal Council: 12% Loss Of Medtech Products Likely On EU MRA Failure

A consortium of Swiss providers, patient groups and health care trade bodies is imploring the federal council to avert a looming patient care crisis in Switzerland if the EU MRA cannot be agreed.

UsernamePublicRestriction

Register

OM016276

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel